These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1623911)

  • 1. The pharmacokinetics of nifurtimox in chronic renal failure.
    González-Martin G; Thambo S; Paulos C; Vásquez I; Paredes J
    Eur J Clin Pharmacol; 1992; 42(6):671-3. PubMed ID: 1623911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of ciprofloxacin in patients with impaired renal function.
    Boelaert J; Valcke Y; Schurgers M; Daneels R; Rosseneu M; Rosseel MT; Bogaert MG
    J Antimicrob Chemother; 1985 Jul; 16(1):87-93. PubMed ID: 2931415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis.
    Kampf D; Borner K; Pustelnik A
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():61-8. PubMed ID: 2286592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers.
    Paulos C; Paredes J; Vasquez I; Thambo S; Arancibia A; Gonzalez-Martin G
    Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):454-7. PubMed ID: 2807618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.
    Flouvat BL; Imbert C; Dubois DM; Temperville BP; Roux AF; Chevalier GC; Humbert G
    Br J Clin Pharmacol; 1983 Jun; 15(6):735-41. PubMed ID: 6871072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
    Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
    J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of meropenem in subjects with renal insufficiency.
    Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
    Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of haemodialysis on the pharmacokinetics of ciprofloxacin.
    Samsom JP
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S23-5. PubMed ID: 3438149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis.
    Brown NM; Reeves DS; McMullin CM
    J Antimicrob Chemother; 1997 Jun; 39(6):803-9. PubMed ID: 9222051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.
    Thompson-Culkin K; Zussman B; Miller AK; Freed MI
    J Int Med Res; 2002; 30(4):391-9. PubMed ID: 12235921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
    Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of nifurtimox and metabolite activity against Trypanosoma cruzi using rat isolated perfused liver.
    González-Martin G; Paulos C; Guevara A; Ponce G
    J Pharm Pharmacol; 1994 May; 46(5):356-9. PubMed ID: 8083806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E; Taburet AM; Landru I; Albin H; Ryckelinck JP
    Eur J Clin Pharmacol; 1987; 31(5):589-93. PubMed ID: 3830244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.